EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

Arzhang Cyrus Javan, Luke, Thomas, David Alain Wohl, Alexander L. Greninger, Christoph L Bausch, Davey Mitchell Smith, Courtney Vail Fletcher, Judith S. Currier, Joseph J. Eron, Jonathan Z. Li, William A. Fischer und 10 weitere

Carolina Digital Repository (University of North Carolina at Chapel Hill) · 21.07.2025

DOI: 10.17615/h4dx-ze98 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 21.07.2025. Verfasst von Arzhang Cyrus Javan und 21 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To address the need for novel COVID-19 therapies, we evaluated the fully-human polyclonal antibody product SAB-185 in a phase 3 clinical trial. Non-hospitalized high-risk adults within 7 days of COVID-19 symptom onset were randomized 1:1 to open-label SAB-185 3,840 units/kg or casirivimab/imdevimab 1200 mg. Non-inferiority comparison was undertaken for the pre-Omicron population (casirivimab/imdevimab expected to be fully active) and superiority comparison for the Omicron population (casirivimab/imdevimab not expected to be active). Primary outcomes were the composite of all-cause hospitalizations/deaths and grade ≥3 treatment-emergent adverse events (TEAEs) through day 28. Secondary outcomes included time to sustained symptom improvement and resolution.Enrollment was terminated early due to low hospitalization/death rates upon Omicron emergence. 733 adults were randomized, 255 included in pre-Omicron and 392 in Omicron analysis populations. Hospitalizations/deaths occurred in 6 (5.0%) and 3 (2.2%) of pre-Omicron SAB-185 and casirivimab/imdevimab arms, respectively (absolute difference [95% CI] 2.7% [-2.3%, 8.6%]), inconclusive for non-inferiority; and 5 (2.5%) versus 3 (1.5%) (absolute difference 1.0% [-2.3%, 4.5%]) for Omicron. Risk ratios for grade ≥3 TEAEs were 0.94 [0.52, 1.71] (pre-Omicron) and 1.71 [0.96, 3.07] (Omicron). Time to symptom improvement and resolution were shorter for SAB-185, median 11 vs 14 (pre-Omicron) and 11 vs 13 days (Omicron) (symptom improvement), and 16 vs 24 days and 18 vs >25 days (symptom resolution), p

Schlagwörter

COVID-19 pandemicOmicron variantmonoclonal antibody therapycasirivimab/imdevimabhigh-risk patientstreatment-emergent adverse eventshospitalization and mortalitysymptom resolutionnon-inferiorityearly treatment

Zitieren

APA

Javan, A. C., Luke, Thomas, Wohl, D. A., Greninger, A. L., Bausch, C. L., Smith, D. M., Fletcher, C. V., Currier, J. S., Eron, J. J., Li, J. Z., Fischer, W. A., Daar, E. S., Team, A. A. S., Ritz, J., Hughes, M. D., Giganti, M. J., Chew, K. W., Neytman, G., …, & Moser, C. (2025). Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/h4dx-ze98

Vancouver

Javan AC, Luke, Thomas, Wohl DA, Greninger AL, Bausch CL, et al. Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2025. doi:10.17615/h4dx-ze98

BibTeX
@article{Javan2025,
  author = {Javan, Arzhang Cyrus and Luke and Thomas and Wohl, David Alain and Greninger, Alexander L. and Bausch, Christoph L and Smith, Davey Mitchell and Fletcher, Courtney Vail and Currier, Judith S. and Eron, Joseph J. and Li, Jonathan Z. and Fischer, William A. and Daar, Eric S. and Team, ACTIV- A Study and Ritz, Justin and Hughes, Michael D. and Giganti, Mark J and Chew, Kara W and Neytman, Gene and Call, Robert S. and Taiwo, Babafemi and Moser, Carlee},
  title = {Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial},
  journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
  year = {2025},
  doi = {10.17615/h4dx-ze98}
}
Kostenlos starten →